Tag: ESC 2022
Cardiovascular News’ top stories of 2022
Which stories, features and interviews captured the attention of the cardiovascular community across...
ESC 2022: Risk score predicts mortality for AF patients after TAVI
Researchers have developed a risk score to predict mortality for patients with atrial fibrillati...
ESC 2022: Survival benefit seen following use of Abbott’s HeartMate 3 LVAD
Abbott has announced the release of late-breaking showing that its HeartMate 3 heart pump extend...
ESC 2022: Transradial access is “gold standard” approach for percutaneous coronary procedures
Transradial access for percutaneous coronary procedures is associated with lower rates of all-ca...
ESC 2022: MASTER DAPT continues to show merit for shortened dual antiplatelet therapy out to 15 months post-PCI
Fifteen-month results from the MASTER DAPT trial have shown that the preserved ischaemic benefit...
ESC 2022: Kidney disease patients with coronary disease see no improvement in survival at five years with an invasive approach
In patients with advanced chronic kidney disease (CKD) and chronic coronary disease, an invasive...
ESC 2022: FRAME-AMI sheds light on best strategy for selecting non-infarct lesions for PCI
Selection of non-infarct related artery (IRA) lesions for intervention using fractional flow res...
ESC 2022: High-risk aortic stenosis could be picked up using AI
Late-breaking research presented at the European Society of Cardiology (ESC) annual congress (26...
ESC 2022: POST-PCI trial finds no benefit to routine functional testing in high-risk PCI patients
Among high-risk patients undergoing percutaneous coronary intervention (PCI), a follow-up strate...
ESC 2022: AI outshines sonographer echocardiogram assessment in EchoNet-RCT
Results of one of the first and only randomised, blinded trials to assess the use of an artifici...
ESC 2022: REVIVED data show PCI does not benefit patients with severe left ventricular dysfunction
Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure ho...
ESC 2022: SECURE trial finds “polypill” results in lower risk of cardiovascular events compared to usual care
Use of a ‘polypill’ after myocardial infarction (MI)—an all-in-one pill containing an antiplatel...
ESC 2022: Timing of antihypertensive medication “makes no difference” to cardiovascular outcomes
The timing of dosing of antihypertensive medication—whether it is taken in the morning or in the...
